Preclinical Development of [(211)At]meta- astatobenzylguanidine ([(211)At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

PURPOSE: [(131)I]meta-iodobenzylguanidine ([(131)I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [(211)At]meta-astatobenzylguanidine ([(211)At] MABG) is an alpha particle emitter wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Batra, Vandana, Samanta, Minu, Makvandi, Mehran, Groff, David, Martorano, Paul, Elias, Jimmy, Ranieri, Pietro, Tsang, Matthew, Hou, Catherine, Li, Yimei, Pawel, Bruce, Martinez, Daniel, Vaidyanathan, Ganesan, Carlin, Sean, Pryma, Daniel A., Maris, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475242/
https://www.ncbi.nlm.nih.gov/pubmed/35861867
http://dx.doi.org/10.1158/1078-0432.CCR-22-0400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475242/
https://www.ncbi.nlm.nih.gov/pubmed/35861867
http://dx.doi.org/10.1158/1078-0432.CCR-22-0400

Ejemplares similares